Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib with Docetaxel and Cisplatin in Gastric/GEJ Cancer
NCT00253370Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2005
- Primary completion
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by National Cancer Institute. Started Oct 2005; status: completed.
02
Drugs
sorafenib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00253370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00253370.